Search filters

Filters
Clear All

Phase

  • 3
  • 3
  • 8
  • 1
  • 16
  • 7
  • 16

Found 16 Hodgkin's Disease trials

A listing of Hodgkin's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)
18 years - 99 years
All genders
Phase 2
Interventional
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL.
 RADVAX FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS
99 years or below
All genders
Phase 2
This is a Phase II single-arm, single-site, open label clinical trial with r/r HL patients, aimed to determine whether a RadVax approach using low-dose RT added to nivolumab can improve response among patients who do not achieve a CR to nivolumab alone. The long-term goal is to develop an effective …
 UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
18 years - 64 years
All genders
Phase 1
Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).  
 CILT + HD-tDCS as a Potential Treatment for Primary Progressive Aphasia
45 years - 80 years
All genders
Phase 2
Primary Progressive Aphasia, or PPA, is a neurodegenerative disease that affects language abilities. A person with PPA may have difficulties speaking, understanding speech, reading, or writing, and these difficulties worsen over time.The purpose of this study is to determine whether a form of non-invasive brain stimulation called High-definition Transcranial Direct …
 ConsCIOUS2: A Prospective Study of the Isolated Forearm Technique Commands  Long-term Sequelae and Electroencephalograph Correlates Following Laryngoscopy and Intubation in patients 18 - 40 years of age
99 years or below
All genders
This a multi-center prospective cohort study of a series of commands surveying responsiveness following laryngoscopy and intubation. Clinical care will not be controlled and will be left to local policy. We will also collect routinely recorded clinical data to frame the observations about IFT responsiveness (please see list below and …
18 years - 99 years
All genders
Interventional
This is a dose range finding safety study of Branaplam administered as weekly oral doses in participants with early manifest HD. The study aims to explore a range of doses to select a safe and tolerable dose that lowers mutant huntingtin protein (mHTT) levels in the CSF to a degree …
99 years or below
All genders
PROOF-HD is a placebo-controlled (double blind) multicenter Phase 3 trial of Pridopidine in Huntington Disease patients. Recruitment: 480 participants at 60 sites, a target of 8 participants per site. Procedures include administration of study drug or placebo in tablet form twice daily for a period of 67-80 weeks with option …
 RADVAX FOR RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: A PHASE II TRIAL OF PEMBROLIZUMAB + LOW DOSE RADIOTHERAPY
18 years - 99 years
All genders
Phase 2
This study plans to treat subjects with pembrolizumab by infusion in combination with radiation therapy to see if the combination is an effective treatment for relapsed/refractory non-Hodgkin lymphoma. Radiation therapy is commonly used to treat relapsed/refractory non-Hodgkin lymphoma. Although pembrolizumab is FDA-approved for some cancers, including Hodgkin lymphoma, it is …
99 years or below
All genders
Phase 2
The study will assess how safe and well-tolerated a combination of the study drugs itacitinib and everolimus in patients with Hodgkin lymphoma. We also hope to learn how effective this experimental combination is in treating Hodgkin lymphoma, when given together.
 A Phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma
18 years - 90 years
All genders
Phase 2
Non-Hodgkin lymphoma is a disease that can be treated effectively with chemotherapy and immunotherapy, but relapses can occur. The purpose of this study is to research the use of a new radioimmunotherapy drug called Betalutin®. Betalutin® is made by using a new antibody, called lilotomab, and attaching a radioactive molecule …
1 - 10 of 16